Although obinutuzumab has not yet received FDA approval in lupus nephritis, findings from a recent survey conducted by ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discussed the Company’s recently announced 6-week interim biomarker data from its ongoing Phase 2a study in ...

AbbVie released positive topline data from its phase 3 UP-AA trial demonstrating safety and efficacy for upadacitinib for ...

Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response. The Independent Data Monitoring Commi ...

A 19-year-old woman with a history of depression and anxiety symptoms was admitted to the hospital because of seizure, ...

Identifying early predictors of chronic kidney disease (CKD) progression in patients with lupus nephritis may help define a high-risk group.

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...

The Lupus Foundation of America, the national force devoted to solving the cruel mystery of lupus, announced the appointment ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...